Under fire for 5 deaths of patients taking Hemlibra, Roche spills details Despite Roche’s insistence that the deaths of five patients taking its Hemlibra for hemophilia were not related to […]
Boehringer Ingelheim taps Facebook Live to spread scleroderma awareness Boehringer Ingelheim is looking to expand its compound nintedanib to treat some scleroderma patients. And in preparation, it’s looking to expand […]
Lilly seeks to quickly advance—and if needed kill—novel drugs to avoid ‘pile-on effect’ in hot targets Eli Lilly is doubling down on novel mechanisms of action to steer clear of […]
Cash reserves running low at KemPharm Money is getting tight at KemPharm, with its liquid cash reserves—currently around $48.5 million—not expected to last through the first quarter of 2019. Source: […]
Gene therapy could promote healing in brain, spinal cord injuries Switching on the LZK gene in mice with spinal cord injuries resulted in a smaller scar, which UT Southwestern researchers […]
Relax, Celgene investors. The situation isn’t as bad as you think: analyst Celgene’s stock has taken a beating in recent months, thanks to a string of bad news. But the […]
Teva won’t owe 5M penalty in Coreg ‘carve-out’ fight with GlaxoSmithKline Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 […]
Denali-WashU team clears Alzheimer’s plaques in mice by targeting a faulty APOE gene A buildup of the beta-amyloid protein in the brain causes the formation of plaques in Alzheimer’s, but […]
Redx pauses WNT cancer trial after first patient suffers adverse events Redx has hit pause on a phase 1/2a trial of its porcupine inhibitor after the first patient to receive […]
Takeda confirms it’s scoping out Shire for a GI-focused buyout bid of up to B Shire has long been a popular buyout target, and it’s the latest to catch Takeda’s […]